Q1 2022 Results

Company overview Financial performance CRM Immunology Financial review Neuroscience 2022 priorities Innovation: Pipeline overview Ophthalmology Appendix Innovation: Clinical trials Respiratory & Allergy Oncology: Solid Tumors Hematology ZolgensmaⓇ - SMN1 gene replacement therapy Study Indication Phase Patients Primary Outcome Measures Arms Intervention NCT05089656 STEER (COAV101B12301) Spinal muscular atrophy (IT administration) Phase 3 125 1. Change from baseline in Hammersmith functional motor scale - Expanded (HFMSE) total score at the end of follow-up period 1 in treated patients compared to Isham controls in the ≥ 2 to < 18 years age group Arm 1: Experimental OAV101. Administered as a single, one-time intrathecal dose Arm 2: Sham Comparator: Sham control. A skin prick in the lumbar region without any medication. Patients Type 2 Spinal Muscular Atrophy (SMA) who are ≥ 2 to < 18 years of age, treatment naive, sitting, and never ambulatory Target Patients Read-out Milestone(s) Publication 2024 TBD 76 Investor Relations | Q1 2022 Results References Abbreviations Biosimilars Global Health 1 NOVARTIS | Reimagining Medicine

View entire presentation